|Brent Rexer, MD, PhD|
Brent Rexer, MD, PhD
Dr. Brent Rexer is Assistant Professor of Medicine in the Division of Hematology/Oncology at Vanderbilt University. He completed the MSTP program at Vanderbilt in 2003 and then stayed at Vanderbilt for internal medicine residency and hematology/oncology fellowship training as part of the ABIM Research Pathway. His research interest is in understanding molecular mechanisms of therapeutic resistance to targeted therapies for cancer and identifying potential therapies to overcome that resistance. In particular, he is focused on studying resistance to lapatinib, a tyrosine kinase inhibitor of the HER2 receptor, in breast cancer.